A method for screening for target cells, a corresponding test kit and a use thereof, a method for screening cells, and a biological culture chip and a preparation method therefor and a use thereof. The method for screening target cells comprises: culturing said candidate single cells within a culture chamber provided with a signal screening layer, the signal screening layer comprising signal molecules for specific recognition of target molecules; on the basis of signals of the signal molecules, selecting target cells suitable for secreting the target molecules. The method for screening cells comprises: arranging candidate cells in a culture chamber to form target antibody-antigen-signal antibody complexes; on the basis of signals of signal molecules connected to the signal antibodies, determining whether the candidate cells are target cells. The biological culture chip comprises a matrix (100), and a biological culture space arranged on the surface of the matrix (100) and used for culturing biological cells.

The present disclosure provides a method for evaluating DNA damage by an analyte and a method for screening a DNA damage inhibitor. According to the present invention, the present invention can quantitatively evaluate the extent of DNA damage by an analyte through visualization.

Provided herein are compositions and methods describing the generation and use of in vitro pro-organs using microparticle scaffolds.

Microfluidic devices and methods for co-encapsulation of a cell and a controlled release particle in one droplet are escribed herein. The devices and methods utilize laminar flow, high shear liquid-liquid interfaces, hydrodynamic vortices, and/or acoustic focusing to increase co-encapsulation efficiency. The precise variation of the droplets microenvironment is enabled by the controlled release particle co-encapsulated with the single cell in each droplet. This capability, coupled with established detection methods, provides an important tool for precise, single cell analysis.

The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.

A device for assembling aggregations of adherent cells includes a gripper moveable within an assembly vessel that fixes aggregations of adherent cells at a membrane of the gripper and, by movement of the gripper, assembles aggregations of cells on a separate membrane within the vessel, thereby creating a three-dimensional assembly of aggregations of cells that fuse and can be employed in surgical procedures as a unitary tissue of adherent cells. The aggregations of cells, as assembled, can assume three-dimensional configurations distinct from any one of the component aggregations of cells assembled.

The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.

The present disclosure relates to a cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs) expressing SOX-1 and SOX-2 and methods of treating a neurological disease or condition comprising systemically administering to a subject a cryopreserved pharmaceutical composition comprising IDPSCs expressing SOX-1 and SOX-2.

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.

Provided a recombinant classical swine fever virus E2 protein comprising at least one mutation at the epitope specifically recognized by the 6B8 monoclonal antibody. Further, the present invention provides an immunogenic composition comprising the recombinant E2 protein of the present invention and the use of the immunogenic composition for preventing and/or treating diseases associated with CSFV in animal. Moreover, the present invention provides a method and a kit for differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.